Multiple myeloma is one of the most common forms of cancer of the immune cells in the bone marrow. It is considered incurable. Even when patients respond to treatment at first, the cancer comes back. Researchers now describes how highly aggressive types of tumors can be detected early on in an article published in the journal Nature Cancer.
To be able to intervene faster and on a more targeted basis, researchers at Charité – Universitätsmedizin Berlin, the Berlin Institute of Health at Charité (BIH), and the Max Delbrück Center teamed up with other partners for a comprehensive study of this disease at the molecular level. The team shows how changes in genetic material affect the protein profile of the tumor cells, and thus the mechanisms involved in the disease.
Multiple myeloma is a form of cancer in which the immune cells in the bone marrow, known as plasma cells, mutate and become cancerous. Plasma cells are responsible for producing antibodies. All humans have many different kinds of plasma cells that form large numbers of different antibodies. This allows the body to recognize and fight various pathogens. In multiple myeloma, a single plasma cell mutates into a tumor cell. That cell reproduces unchecked, forming a monoclonal cell population. This means many cells are formed, all of them exactly the same and genetically identical at first. The mutated cells often also produce large volumes of antibodies or fragments of them – but they do not function properly.
Over the course of the disease, most patients develop tumors at various locations in the bone marrow, hence the “multiple” in the disease’s name. Immunodeficiency, kidney failure, bone loss, and bone fractures are just some of the consequences of this uncontrolled cell growth. Despite advances in treatment and the introduction of new gene and cell therapies, there is no cure for multiple myeloma at present. With this issue in mind, a team of researchers led by Jan Krönke from the Department of Hematology, Oncology and Cancer Immunology at Charité and Dr. Philipp Mertins, head of the Proteomics technology platform of the Max Delbrück Center and BIH, set out in search of new approaches to diagnosis and treatment.
No two cases of cancer are alike, and multiple myeloma is no exception. Tumors develop differently in different individuals, including at different rates. This makes it more difficult to predict how the disease will progress and choose the optimum treatment. While the mutated plasma cells do not spread much in some cases, in others they are extremely aggressive, leading to a poor prognosis.
But what causes so much divergence in the course of multiple myeloma? In cooperation with protein analysis experts from the Max Delbrück Center and BIH, the researchers conducted a detailed study of genetic and molecular changes occurring in the tumor cells in a group of more than one hundred patients. The study included data from patients in the German Multiple Myeloma Study Group (DSMM), which is coordinated by the University Hospital of Würzburg. This allowed the researchers to include clinical data on patients who had received standardized treatment over a period of eight years or more following initial diagnosis.
While changes in the genome and their effects on the proteome are already well described for other types of cancer, this is the first detailed proteo-genomic study of multiple myeloma. “Genetic data alone is insufficient to explain the mechanisms involved in this disease,” Mertins says. “We wanted to know the consequences of genetic changes at the protein level and compare this molecular biology data against the actual course of the disease in patients.” The team was supported in collecting and analyzing the large volumes of data by experts at Charité, BIH, and the German Cancer Consortium (DKTK).
Cutting-edge mass spectrometry methods made it possible to map the protein profile of mutated plasma cells and compare it against that of healthy plasma cells in people without the disease. The researchers found that both genetic changes and changes in signaling pathways lead to uncontrolled activation of cancer cells. Regulatory processes at the protein level had the stronger influence. The researchers identified a protein constellation that suggests the disease will take a particularly aggressive course, regardless of other known risk factors.
“Our findings will help subcategorize patients more effectively going forward, personalizing their treatment,” Krönke concludes. “We’ve identified key proteins and signaling pathways that can serve as the basis for even more effective, better tolerated treatments for multiple myeloma, for example for immune therapies such as CAR T-cell therapy.” In further steps, the researchers plan to study which of the target structures they have identified are in fact good candidates for new therapeutic approaches.
The study is a crucial resource for research and applied development, says Dr. Evelyn Ramberger, first author of the study: “To make the complex data set manageable, we programmed an interactive, freely available online tool.” This has given cancer researchers easy access to the results, so they can use the information to develop new therapies and tests to help guide treatment. For example, it may be possible to treat patients with an especially aggressive form of multiple myeloma with more intensive therapies right at the outset.
Original publication:
Ramberger, E., Sapozhnikova, V., Ng, Y.L.D. et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer 5, 1267–1284 (2024).
Source: DKTK
Study on new genetic risk factor for cardiovascular diseases - influence on new diagnostic and treatment methods for prevention.
Dangerous deposits in the blood vessels, known as plaques, pose a risk of heart attacks or strokes. A research team from the University Institute of Cardiogenetics led by DZHK scientist Dr Redouane Aherrahrou, in collaboration with international partners, has now been able to show that certain genes influence the stability of plaques and thus the risk of cardiovascular disease. The study was published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.
Cardiovascular diseases such as heart attacks and strokes are among the most common causes of death worldwide. Dangerous deposits in the arteries, so-called atherosclerotic plaques, play a central role in this. A better understanding of the mechanisms that lead to the stabilisation or destabilisation of these plaques is therefore of great importance.
The team led by Dr Redouane Aherrahrou has combined genetic data on heart attacks from the last twenty years with smooth muscle cells from blood vessels of 151 healthy heart transplant donors. These cells have an important function in the formation and stabilisation of plaques.
"In our study, we were able to show that genetic differences can influence the release of proteins that contribute to the stabilisation of atherosclerotic plaques," explains Dr Aherrahrou. "What is particularly exciting is that we were able to gain new insights by combining the information about these proteins with genetic data using modern bioinformatics methods."
The research team found several genetic variants that increase the risk of a heart attack. A specific variant in the LTBP1 gene is particularly interesting, as increased activity of this gene leads to more stable plaques. "Regulating the LTBP1 gene could be a promising future therapeutic option," says Dr Aherrahrou.
These findings are not only important for science, but could also have a significant impact on the development of new diagnostic and treatment methods for the prevention of heart attacks and strokes. "Our research offers new approaches for identifying and treating patients at higher risk of cardiovascular disease," summarises Dr Aherrahrou.
Original publication: Secreted Protein Profiling of Human Aortic Smooth Muscle Cells Identifies Vascular Disease Associations. Aherrahrou, R. Baig, F., Theofilatos, K. et al., Arterioscler Thromb Vasc Biol. 2024 Apr;44(4):898-914.
Source: DZHK
In stroke patients, the so-called troponin marker helps to assess the risk of an associated heart attack. This is a result of a joint study by DZNE and the DZHK, both of which are members of the German Centers for Health Research. The findings could pave the way for better treatment.
Patients with acute stroke often also suffer heart complications. In individual cases, however, it is difficult to assess whether stress-mediated heart damage is present or an acute heart attack, i.e. a circulatory disorder of the heart muscle that needs to be treated as quickly as possible. Determining the troponin level in the blood helps with the medical decision. This checks for a protein that comes from the heart muscle cells. If its concentration is very high, this indicates a heart attack – and then cardiac catheterisation (coronary angiography) is required. If then a vascular occlusion or a critical narrowing is detected, a “stent” can be inserted: This implant is used to widen the vessels and improve the heart’s blood supply.
In everyday clinical practice, cardiac catheterisation is currently only performed in around one to two percent of stroke patients. This could change thanks to an interdisciplinary research collaboration between cardiologists and neurologists. The joint PRAISE study by DZHK and DZNE – in which around 250 adults with acute stroke and highly elevated troponin levels were examined – revealed that half of all patients actually also had a heart attack.
“This is a surprisingly high proportion, at least from a neurologist’s point of view; we had not expected so many heart attacks,” says Prof. Matthias Endres, Director of the Department of Neurology with Experimental Neurology at Charité - Universitätsmedizin Berlin and researcher at DZNE’s Berlin site. He led the study together with his colleagues Prof. Christian Nolte and Prof. Ulf Landmesser from the Deutsches Herzzentrum der Charité.
According to the study, around 20 per cent of stroke patients were affected by a type 1 heart attack, which should be treated immediately. A further 30 per cent of patients were diagnosed with a type 2 heart attack, which is triggered by a lack of oxygen in the heart, but in which no blood clots or vascular constrictions form.
In addition, the PRAISE study found that a more than five-fold increase in troponin levels indicated a high probability of a type 1 heart attack. “This is a relevant finding,” says Nolte. “The new threshold value can help to decide which patients with a stroke should undergo coronary angiography.” If there is a vascular occlusion or a critical narrowing of the coronary arteries, a stent can be applied. The hope is that this will improve the prognosis for patients and reduce their mortality rate.
The study was a first step in this direction. “PRAISE is a diagnostic study to better understand the mechanism of heart damage,” emphasises Endres. “Next, we want to conduct a treatment study to investigate whether we can improve the prognosis of stroke patients with fivefold elevated troponin levels with the help of a cardiac catheter and the appropriate treatment.” Only then will it be possible to make binding recommendations for clinical practice.
Original publication: Type 1 Myocardial Infarction in Patients With Acute Ischemic Stroke. Nolte, C.H.von Rennenberg, R.Litmeier, S. et al. JAMA Neurol. 2024;81(7):703–711.
In chronic hepatitis B, the liver contains immune cells that could destroy hepatitis B virus-infected cells but are inactive. An international team led by Percy Knolle and Ulrike Protzer at the Technical University of Munich (TUM) has discovered that cells in blood vessels in the liver start a kind of ‘sleep timer’ that switches off immune cells after a certain period of time. Targeting this mechanism could be a starting point for immunotherapies.
Hepatitis B is a widespread disease. According to estimates by the World Health Organisation (WHO), 250 million people worldwide suffer from chronic hepatitis B. The most common health consequence of chronic hepatitis B is liver damage. Often, the body's immune response against infected cells causes the damage, not the virus itself: Immune cells trigger inflammatory processes that can lead to fibrosis – scarring of the liver tissue – and liver cancer.
"In chronic hepatitis B, the body's immune system tries to destroy infected liver cells, thereby causing long-term damage, and still does not get rid of the virus," says Percy Knolle, Professor of Molecular Immunology at TUM and scientist in the research area Hepatitis of the German Center for Infection Research (DZIF). Notably, in chronic infections, some of the immune cells whose receptors could recognise and destroy the Hepatitis B virus are inactive.
A team led by DZIF scientists Prof. Percy Knolle and Prof. Ulrike Protzer at Technical University of Munich and Helmholtz Munich describes the reason for this in the scientific journal Nature. The hepatitis B virus specifically infects hepatocytes. These cells make up the largest part of liver tissue. They are supplied by small blood vessels that are lined with endothelial cells. Immune cells that enter the liver via the blood only reach infected hepatocytes through special openings in these endothelial cells. They protrude extensions through these openings to reach the infected hepatocytes and trigger their destruction. In doing so, they are forced into close contact with the endothelial cells.
"We show that the endothelial cells start a kind of molecular sleep timer in certain immune cells – cytotoxic T cells that can detect hepatocytes infected with the hepatitis B virus," says Dr. Miriam Bosch, first author of the study. "The timer starts running as soon as the T cells get into contact with the infected hepatocytes." The longer the T cells are in contact with the endothelial cells, the weaker their activity becomes – comparable to the volume of music decreasing before the sleep timer stops it altogether.
Specifically, the endothelial cells use the cAMP-PKA pathway to switch off the signal transmission of the receptors with which the T cells recognise the Hepatitis B virus and through which they are activated. As a result, the immune cells no longer attack the infected cells and, above all, are unable to proliferate.
"We think that this mechanism evolved to protect the liver," says Percy Knolle. "The time limit prevents immune cells from proliferating too much during an infection and potentially critically damaging the liver when destroying infected hepatocytes." In some cases, however, the time window for fighting the virus is apparently too short, and the virus escapes the control by the immune system. As new T cells keep attacking the infected hepatocytes, chronic hepatitis B leads to organ damage despite the protective mechanism.
"Now, the search begins for ways to influence this mechanism," says Percy Knolle. "By doing so, we might support the immune system in effectively combating a chronic hepatitis B infection." On the one hand, targeted immunotherapies are conceivable in which T cells are manipulated in such a way that they are no longer receptive to the signals from the endothelial cells. On the other hand, it may also be possible to switch off the mechanism by small molecules targeting this mechanism. To achieve this, however, it is crucial that the active agents are selectively delivered to the immune cells in the liver to avoid impairing vital processes in other cells of the body. The researchers believe that such therapies could enhance the effect of vaccinations and thus help to combat chronic hepatitis B, which is particularly prevalent in poorer regions of the world.
Original publication: A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Bosch, M., Kallin, N., Donakonda, S. et al. Nature Jul 2024;631: 867–875.
More than 170 researchers and clinicians from the eight German Centers for Health Research (DZGs) and invited guests from the world of politics shared insights on current DZG research projects at the 2nd DZG Munich Day in Munich on July 12, 2024. Lively networking and discussion between participants from the various DZGs offered a unique opportunity to develop new joint research projects and innovative research approaches.
“This is already the second DZG Munich Day. For us in Bavaria, that is enough to call it a tradition,” said Markus Blume, Bavarian State Minister for Science and the Arts, in his welcoming message. He thanked the DZGs for their outstanding work and congratulated them on their successes. The mission of the DZGs is to defeat the most pressing widespread diseases: diabetes, infections, lung diseases, cancer, cardiovascular, neurodegenerative and mental diseases as well as diseases in childhood and adolescence.
“The DZGs have already achieved important breakthroughs in the prevention, diagnosis and treatment of widespread diseases,” emphasized DZG speaker Martin Hrabě de Angelis. Among other things, they have advanced the development of precision medicine, company spin-offs and patents, influenced medical guidelines and developed innovative medical devices. This has been made possible by the unique structure of the DZGs. “The German Centers for Health Research are an essential bridge from research to practice,” underscored Matthias Tschöp, CEO of Helmholtz Munich. He reported that international partners are inquiring about the DZG model.
“Munich is the only location in Germany where all eight DZGs are active,” highlighted Thomas Romes from the Department of Life Sciences of the Federal Ministry of Education and Research (BMBF) in his welcoming address. The speakers of the Munich-based DZGs gave an overview of their respective main research topics.
The events focused on presentations of cross-DZG research projects. Other topics included talks on “DZG activities and synergies” by Martin Hrabě de Angelis, the “Munich Medicine Alliance” by Matthias Tschöp (CEO, Helmholtz Munich) and “Patient participation in the DZGs” by Astrid Glaser (German Center for Diabetes Research, DZD) and Stefan Leucht (German Center for Mental Health, DZPG).
In addition to the scientific lectures, the presentation of three poster awards for the first time was also an important part of this year’s program. 24 young talents had the opportunity to pitch their research work in a one-minute presentation and exhibit it with a poster. Maike Becker (German Center for Diabetes Research, DZD), Michael Gerckens (German Center for Lung Research, DZL) and Cheng He (German Center for Cardiovascular Research, DZHK) were honored with a poster award.
Planning is already underway for the 3rd DZG Munich Day next year.
Further information and picture gallery
Source: DZD
People who are severely overweight (obese) not only exhibit altered risk behavior, but also changes in their metabolism and psyche. It was previously assumed that severely obese people are more impulsive and show an increased willingness to take a risk. Scientists from the DZD partner German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have now investigated whether massive weight loss leads to an improvement in metabolic and psychological states and whether decision-making is improved. The results were published in the journal Clinical Nutrition.
Our behavior depends on many factors. On the one hand, it is an expression of our personality, but it is also controlled by internal signals, such as glucose metabolism and our mood. Studies have shown that people with obesity are influenced by these factors in a completely different way. Glucose metabolism and mood are impaired in this case and therefore do not provide signals that form a reliable basis for taking decisions any longer.
Beatrix Keweloh, a doctoral student in the Department of Neuroscience of Decision and Nutrition, and her team investigated in an intervention study whether this condition can be reversed by massive weight loss. They recruited 62 test subjects aged between 18 and 75 with severe obesity (BMI > 35 kg/m2) and prescribed them an intensive 10-week diet with a daily energy intake of 800 kilocalories. At the beginning and end of the intervention, the participants' weight and body fat were measured, their mood was recorded using a questionnaire and their willingness to take a risk was determined using a computer-based test.
As expected, after the 10-week diet there was a significant reduction in the body mass index (BMI) and the HbA1c level as a marker for glucose metabolism, as well as a significant improvement in mood. In addition, the scientists were able to demonstrate a positive change in behavior, as the weight loss led to risk-avoiding decisions. Accordingly, risk behavior in obesity appears to be highly dependent on the BMI. “Our results have also shown that the metabolic factor HbA1c becomes the leading predictor of risk-taking after weight loss,” says first author Beatrix Keweloh.
The study also showed that mood loses its influence on decision-making after weight loss. The participants' risk behavior was therefore more strongly influenced by metabolic signals than by emotional ones. “We have shown that weight loss has a positive effect on glucose metabolism and mood and, in particular, that it is possible to restore the function of glucose metabolism as a control signal,” summarizes Keweloh.
The study reveals that there are complex interactions between weight loss as well as metabolic and psychological factors with regard to risk-taking. The BMI seems to play a central role. As a reduced willingness to take a risk is associated with a healthier lifestyle, it is an important prerequisite for weight loss and maintaining a healthy body weight.
Accordingly, intervention strategies to support weight management should consider both metabolic and psychological factors to prevent relapse into unhealthy behaviors and promote metabolically driven decisions.
“This study is one of the first of its kind because it takes into account both metabolic and psychological factors in overweight people,” summarizes Prof. Soyoung Q Park, Head of the Department of Neuroscience of Decision and Nutrition. “It therefore provides an important contribution to research in this field. On the other hand, it shows that we are only at the beginning and need to do more research to understand exactly how energy balance and psyche affect our decisions.”
Original publication: Weight Loss Impacts Risky Decisions in Obesity. Keweloh, B., Terenzi, D., Froehlich, E. et al. Clin. Nutr. 2024;43(6): 1270-1277.
Source: DZD
Anxiety, hyperkinetic syndrome, learning disabilities, depression, addictions, and eating disorders: The list of mental disorders affecting children and adolescents is long. If left unaddressed during childhood and adolescence, mental health problems often carry over into adulthood. "One in five children and adolescents is affected by mental disorders," says Falkai. "In adults, the figure rises to one in four. This makes mental illness one of the greatest challenges in medicine.”
As they grow older, adolescents are exposed to stress as they finish school, begin a professional career, form their own social networks, and find social roles. Nevertheless, the risk of mental illness is not only due to the maturation process. Research at the DZPG focuses on specific risk factors. Falkai explains: "The number of mental disorders in children and adolescents increased significantly during the coronavirus pandemic, with contact restrictions, loneliness, and higher levels of domestic violence". The increase is confirmed by a study conducted by the BKK umbrella organization on behalf of the Children's Health Foundation. It shows that in the pandemic years 2020 and 2021, 15-19-year-old female policyholders in particular suffered from psychological symptoms. Anxiety and adjustment disorders were observed at above-average rates. And the next crisis is already here: "We are also observing an increase in post-traumatic stress disorder and depression due to external stressors such as armed conflicts.”
"Many of the DZPG's research projects are aimed at prevention," says Prof. Falkai. "Many mental disorders develop their first symptoms even before they become manifest. In practice, these first external signs are often unspecific: "They include sleep disturbances, inner restlessness, and physical complaints such as stomach aches, headaches, and back pain. Eventually, this development can lead seamlessly to anxiety disorders. A deterioration in concentration and therefore in school performance is also frequently observed. Experts are registering increasing numbers of cases in such areas as well: Among schoolchildren, potentially psychosomatic complaints such as headaches, stomachaches, and backaches, as well as problems falling asleep and depression, have increased significantly over the years. That's one of the findings of WHO's Health Behavior in School-aged Children (HBSC) study.
The DZPG's research on primary prevention is aimed at this early stage: the goal is to reduce the likelihood that children and adolescents will develop mental disorders. Prof. Dr. Andreas Meyer-Lindenberg, Director of the Central Institute for Mental Health in Mannheim and spokesperson for the DZPG, explains: "The first step is to measure mental health at all. The DZPG is currently carrying out such a measurement in Bochum with the German Health Barometer. A representative sample of the population is regularly asked about their mental health. This makes it possible to measure changes in the mental health of the population - for example, during an economic crisis or a pandemic - so that measures can be taken to prevent a collapse.
The risk of mental illness is not the same for all children and adolescents in Germany: "We know risk factors that can trigger or exacerbate mental illness. Premature birth is one of them," says Falkai. This is the focus of the DZPG site in Tübingen. As part of an early detection program, the families of premature babies are closely monitored in order to identify possible early symptoms of mental illness and to reduce the family stress caused by the premature birth. At the same time, a large cohort of twins is being followed to understand risk and resilience factors, identify early symptoms and offer intervention options.
However, risks also arise in the further course of the disease. Prof. Dr. Dr. Andreas Heinz, Director of the Department of Psychiatry and Psychotherapy CCM at the Charité - Universitätsmedizin Berlin and spokesperson for the DZPG: "One factor is socio-economic status, particularly with regard to barriers to access to health care, but also mental health literacy: How much do I know about mental health? Growing up in an urban area and having one or both parents unemployed are also risk factors for mental disorders. Minority status is another risk factor. For this reason, the DZPG launched a project in the Wattenscheid district of Bochum. An above-average number of people there live in precarious circumstances, have a migration background, or are affected by unemployment. Under the motto "Urban Mental Health" (UMH), the Research and Treatment Center for Mental Health (FBZ) at the Ruhr University Bochum is developing a novel prevention concept. For the first time, it brings together science, policy, and practice to improve the mental health of children and adolescents. The project aims to improve the mental health of teachers by increasing their resilience, and to develop a curriculum for students to improve their mental health literacy. If successful, it could become a blueprint for the whole of Germany.
Researchers at the FU Berlin are focusing on children of parents who have difficulty dealing with their children because of their own mental stress. This can mean, for example, that one or more parents suffer from a mental illness (e.g. depression or anxiety disorders) or have limited social or financial resources. Research shows that such stressors can be associated with increased parental stress, which in turn can make it more difficult to communicate and interact with one's children. An app is being developed as a low-threshold way for parents to strengthen their own mental health and promote positive parenting behaviors.
The DZPG is also conducting research into secondary prevention, i.e. improving the chances of treatment by detecting diseases at an early stage. Falkai: "The DZPG is currently evaluating centers for the early detection and initial treatment of mental illnesses and wants to improve the information available to the public. The goal is for children, adolescents and their families to have access to competent early detection centers that specialize in mental disorders. "Only experts can distinguish symptoms that indicate a mental illness from those that are part of normal maturation and development processes.”
References: Kindergesundheitsbericht 2023 der Child Health Foundation; Health Behavior in School-aged Children (HBSC)-Studie, WHO
Source: DZPG
Teams from the Medical Faculty of Heidelberg University, the European Molecular Biology Laboratory (EMBL) Heidelberg, the German Cancer Research Center (DKFZ), and Leiden University have shown in mice that certain immune cells keep lung tumors in check if they have previously been treated with iron nanoparticles. The recently published work was funded by the Translational Lung Research Center Heidelberg, a partner of the German Center for Lung Research.
Certain immune cells, known as macrophages, are attracted to tumors and can attack them - or protect them from other immune cells and chemotherapy. Introducing iron particles can reliably steer the macrophage behavior towards cancer defense. This discovery was made by a team led by Professor Martina Muckenthaler, Medical Faculty Heidelberg, University of Heidelberg, and group leader at the Molecular Medicine Partnership Unit (MMPU), a cooperation between the Medical Faculty Heidelberg and EMBL Heidelberg. The scientists investigated a form of non-small cell lung carcinoma that initially responds well to targeted drugs, but becomes resistant over time and grows back. In mice suffering from this type of lung cancer, specially prepared iron nanoparticles were able to slow tumor regrowth, as the team recently reported in the journal ACS Nano. How long this effect lasts and whether it is transferrable to humans cannot yet be determined from these results. Nevertheless, the team believes that this novel immunotherapy has the potential to enhance the effects of current therapies.
The research was conducted in collaboration with the groups of Prof. Dr. Rocio Sotillo, Director of the Division of Molecular Basis of Thoracic Tumors at DKFZ, Prof. Dr. Matthias W. Hentze, Director of EMBL, and Prof. Dr. Matthias Barz, Director of the Department of BioTherapeutics at the Leiden Academic Centre for Drug Research (LACDR), University of Leiden, Netherlands. The lead authors are former doctoral students Natalie K. Horvat, MMPU, and Sara Chocarro, DKFZ.
The idea of an iron booster for immune cells came from observations in a completely different disease affecting the blood: When deformed red blood cells are broken down in hereditary sickle cell anemia, the iron contained within them enters the blood and tissues. "When macrophages in the liver absorb this iron, they attack surrounding liver cells and cause tissue damage," says Professor Muckenthaler, who investigates various disorders of iron metabolism at the Center for Translational Biomedical Iron Metabolism Research at Heidelberg University Hospital. "As red blood cells are also broken down in the tumor environment, we took a closer look at the tumor microenvironment."
Lung tumors stimulate the growth of blood vessels in their surroundings in order to be better supplied with oxygen and nutrients. From these blood vessels, red blood cells enter the often inflamed tissue and are broken down by macrophages. Their iron accumulates in the macrophages. In tissue samples from patients with non-small cell lung carcinoma (NSCLC), the team previously found that if such an "iron curtain" is present around the tumor, the tumors remain smaller and patients have a better prognosis than those without iron accumulation. "The macrophages in the vicinity of the tumors are more aggressive against cancer. We wanted to take advantage of this natural activation of cancer defense," the scientist explains.
The team administered specially prepared iron nanoparticles from Professor Barz's laboratory to mice suffering from a subtype of human lung tumors, so-called ALK-positive NSCLCs, via the respiratory tract. The animals had initially been treated with the common tumor drug crizotinib, which precisely targets an altered protein of this type of cancer and temporarily suppresses the tumors completely. "Targeted drugs such as Crizotinib are a major advance in the treatment of this specific type of cancer. Unfortunately, the tumors become resistant after an average of 19 months. If we were able to additionally activate the immune system with the iron booster, we could potentially gain disease- and symptom-free time for patients,” says cooperation partner Professor Sotillo.
When macrophages took up the iron nanoparticles, they released substances that harmed the cancer cells and attracted further immune cells. After treatment with crizotinib, the tumors grew back at a significantly slower rate over the two-week trial period. There were no side effects. "These results do not yet say anything about whether and for how long lung cancer patients would benefit from such treatment. But they show a promising approach that we would also like to test in other forms of lung cancer as well as liver tumors and breast cancer,” says Muckenthaler.
Non-small cell lung cancer (NSCLC) accounts for about 80 percent of all lung tumors. The subtype of ALK-positive non-small cell lung cancer, affecting about 5 percent of NSCLC patients, is characterized by a specific genetic alteration (EML4-ALK fusion oncogene). Patients with this cancer type usually have never or rarely smoked. The usual treatment consists of treatment with targeted inhibitors such as Crizotinib. However, these tumors respond poorly to common immunotherapies.
Original publication: Superparamagnetic Iron Oxide Nanoparticles Reprogram the Tumor Microenvironment and Reduce Lung Cancer Regrowth after Crizotinib Treatment. Horvat, N.K., Chocarro, S., Marques O. et al. ACS Nano. 2024;18(17):11025-11041.
Source: DZL
Research for health and the prevention and better treatment of common diseases are the goals of the German Centers for Health Research (DZG). At the 2nd DZG Munich Day on July 12, 2024, the eight DZG in Munich will provide an overview of scientific highlights and an insight into joint research. Other focal points include the participation of patients and the presentation of poster awards.
Many people still suffer from common diseases such as diabetes, infections, cancer, cardiovascular and lung diseases as well as neurodegenerative and mental disorders. In the eight centers for the respective widespread diseases, researchers and clinicians are working successfully to bring new results from science into practice more quickly. "The German Centers for Health Research carry out cutting-edge translational research. People benefit from this through more targeted prevention and more precise treatment," emphasizes Prof. Martin Hrabě de Angelis, current spokesperson of the DZG.
Although the various common diseases appear to be quite different, there are often connections that are important for the development of new therapies and research methods. The active networking of the various DZGs offers a unique opportunity to develop innovative research approaches. A special focus at the 2nd DZG Munich Day will therefore be on cooperation between the centers. Current transdisciplinary projects will be presented, including on intermittent fasting, the identification of disease causes and biomarkers or research into cross-disease changes in the protein TREM2, which drives the brain's immune cells to peak performance.
Following last year's successful start, the DZG Munich Day is being held for the second time. The event will be opened by welcoming addresses from Thomas Romes (Department of Life Sciences, Federal Ministry of Education and Research (BMBF)), Markus Blume (Bavarian State Minister of Science and the Arts), Matthias Tschöp (CEO, Helmholtz Munich), Stephanie E. Combs (Dean, TUM School of Medicine and Health) and Markus M. Lerch (Medical Director, LMU Klinikum). The work of the DZG will then be presented. The DZG's research in Munich will be presented by the site speakers.
Patients are playing an increasingly important role in research. Their experiences and perspectives on living with a disease can provide valuable input for researchers. At the event, the DZG will present how they actively involve patients in their work (patient participation).
The extensive program also includes posters presenting the latest results. This gives young talents the opportunity to present their research and talk to other researchers. The best three posters will receive awards.
The aim of the 2nd DZG Munich Day is to further expand cross-DZG exchange, strengthen existing collaborations between the various DZGs in Munich, establish new contacts and make even better use of synergies.
More informationen on 2nd DZG Munich Day
Program of the 2nd DZG Munich Day
Source: DZD
United against common diseases! This is the mission of the German Centers for Health Research (DZGs). Their scientists are working to optimize the translation of research results into patient care, thereby significantly improving the prevention and treatment of these diseases.
It´s time: project start for the winners of this year's DZG-overarching research project in Dresden. The awardees were honored at the German Cancer Consortium (DKTK) Dresden by Prof. Mechthild Krause and Prof. Michele Solimena.
At the annual joint symposium, the three Dresden DZGs – the Paul Langerhans Institute Dresden (PLID) of the German Center for Diabetes Research (DZD), the German Center for Neurodegenerative Diseases (DZNE), and the aforementioned DKTK – once again announced seed funding for cross-DZG projects this year. The aim of this funding is to enable new translational activities between the DZGs in Dresden that arise at the thematic interfaces of the centers.
This year, one project team received €10,000 in seed funding. In the project "Metabolic-epigenetic crosstalk as a driver of aging, disease and cognitive decline", Sara Zocher (DZNE) and Zeina Nicola (DZD/PLID) want to gain new insights into the causes of brain ageing. In collaboration with Claudia Peitzsch, they are using the Mass Cytometry Facility of CRTD and use metabolic targeting to investigate the neuronal epigenome as a potential therapeutic intervention. The long-term aim is to counteract age-related brain dysfunction in this way.
Diabetes, cancer, and dementia: As different as these diseases may seem, there are often connections that are relevant for the development of therapeutic approaches and diagnostic methods. The active networking of the DZGs thus represents a unique opportunity to develop completely new and innovative research approaches. Dresden is a pioneer in this field, as the three Dresden-based DZGs have been closely connected for several years.
Diabetes, cancer and dementia: as different as these diseases may appear, there are often crosslinks that are relevant for the development of therapeutic approaches and investigative methods. The active networking of different DZGs thus reflects a unique opportunity to develop completely new and innovative research approaches. Dresden is a pioneer in this respect, as the three Dresden-based DZGs have been closely connected for several years.
Source: DZD
CRISPRi is based on the CRISPR-Cas genome editing system but lacks the ability to cut DNA, a so-called "dead CAS" (dCAS) and is fused to a KRAB repressor domain. Using a short RNA as a molecular guide dCas9 can bind to specific DNA sequences. As a result, the target region in the genome is epigenetically silenced, and a gene can no longer be read. This blockade is called "epigenetic silencing".
To introduce the CRISPRi system into the heart muscle cells of mice, the researchers used adeno-associated viruses (AAV), which do not integrate into the genome. One challenge was to package the entire system into the limited genomic capacity of the AAVs. The researchers succeeded in doing this by using a particularly small dCAS. Although other viral vectors have more capacity in this respect, they cannot efficiently reach heart muscle cells or integrate into the genome.
Dr Patrick Laurette and his colleagues at Heidelberg University Hospital demonstrated how well epigenetic silencing with the AAV-CRISPRi system works in heart cells for several genes and enhancers. The activity of some genes decreased by up to 95 percent. Enhancers are regulatory elements that can fine-tune gene expression from distant genomic regions.
"The complexity of the mammalian organism is the result of around one million regulatory elements. There are between fifty and one hundred thousand of these enhancers in heart muscle cells alone," says Prof. Ralf Gilsbach. They are now focusing on modulating these regulatory elements using their new method to treat diseases such as heart failure or cardiac arrhythmia.
Gilsbach emphasizes the translational significance of this approach, which makes it possible to specifically influence gene expression in vivo without changing the DNA sequence. The method is also titratable, meaning it can be regulated and its effect can be reversed. Compared to other methods, such as genetic knock-out, in which genes are destroyed, the AAV-CRISPRi system offers a more precise imitation of natural regulatory mechanisms.
Methodically optimized and further developed, the procedure could also be used for human therapy in the long term. "I am convinced that this approach has translational significance, even if it is difficult to predict how quickly development will continue here," says Gilsbach.
There are already numerous companies that are considering AAVs to deliver CRISPR components for therapies. Among other things, they are working on avoiding unwanted antibody reactions. This is because humans have antibodies against AAV and often also against the CRISPR protein derived from bacteria.
Original publication: In Vivo Silencing of Regulatory Elements Using a Single AAV-CRISPRi Vector. Laurette, P., Cao, C., Ramanujam, D. et al. Circ Res. 2024;134(2):223-225.
Source: DZHK
On June 12, 2024, a joint strategy paper "National Strategy for Gene and Cell Therapies" was presented to Federal Research Minister Bettina Stark-Watzinger. It was conceived by stakeholders from science, industry, politics, authorities, foundations, patient organizations and with the participation of the German Centres for Health Research.
In fall 2022, the Federal Ministry of Education and Research (BMBF) commissioned the Berlin Institute of Health at Charité (BIH) to coordinate the creation of a national strategy for gene- and cell-based therapies. Around 150 experts from various stakeholder groups drew up the paper and developed a roadmap for improving healthcare and strengthening Germany as a location for gene- and cell-based therapies. Several experts from the German Centers for Health Research (DZG) were also represented in the various working groups.
Gene and cell therapies (GCTs) are some of the key technologies driving innovation in biomedical research and patient care. They are not only used to modulate disease processes and alleviate symptoms, but also directly address the genetic causes of diseases. This opens promising perspectives for patients suffering from severe and rare diseases for which no treatment currently exists.
In order to improve patient access to gene and cell therapies and to strengthen Germany as an international hub for research and innovation in this field, the BMBF commissioned the BIH in fall of 2022 to coordinate and oversee the development of a National Strategy for Gene and Cell Therapies. This strategy was presented to the Federal Minister of Education and Research, Bettina Stark-Watzinger, on June 12, 2024.
“The National Strategy for Gene and Cell Therapies is an important step towards securing and expanding Germany's position as a centre of biomedical innovation. Our declared aim is to create new treatment options for patients in the long term. I am very pleased that we have succeeded in bringing together so many stakeholders from different areas and jointly developing the National Strategy. This collaboration between science, industry, the public sector and society is an important key to success. I would like to thank all those involved for their great commitment. With this spirit of optimism, we should now move forward together in a national network." says Federal Research Minister Bettina Stark-Watzinger.
The National Strategy is chiefly characterized by its multi-stakeholder approach, which brought together a wide range of views and interests from science, business, politics, society and patient groups. Several experts from the DZG were also represented in the various working groups formed for this purpose.
The fields of action include the following topics:
I. Stakeholder networking and support
II. Training and development of skills
III. Technology transfer
IV. Standards, norms and regulatory framework
V. Improvement of quality and capacity for good manufacturing practice (GMP) production
VI. Research and development
VII. Marketing authorization and translation into patient care
VII. Interaction with society
The strategy emphasizes the tremendous potential that the cutting-edge field of gene and cell therapy has for improving patient care and the healthcare industry and for strengthening Germany as a location for pharmaceuticals and innovation. Yet measures must be taken to accelerate the translation of findings from Germany’s strong basic research programs into clinical practice, while at the same time making gene and cell therapies not only safe and efficient but also affordable and widely accessible.
The proposed measures will now be implemented step by step in collaboration with all stakeholders. A number of other activities have already been initiated alongside the drafting of the strategy. These include the creation of a National Network Office for Gene and Cell Therapies, the establishment of the nationwide entrepreneurship program GeneNovate, the offering of low-threshold advice on regulatory issues and the laying of the groundwork for funding to support researchers and projects in the field of gene and cell therapy. The Network Office is tasked with building a national GCT community that brings together all stakeholder groups through independent, cross-site information exchange and networking. A total of 48 million euros is available for the design and implementation of the strategy's measures in the period 2023-2026.
Download: National Strategy for Gene and Cell therapies
Source: BIH press release
You are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from OpenStreetMap. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Mapbox. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers.
More Information